Scarica l'app Stockscreener
4.55
2.48%
0.11
Dopo l'orario di chiusura:
4.54
-0.010
-0.22%
Precedente Chiudi:
$4.44
Aprire:
$4.53
Volume 24 ore:
2.27M
Relative Volume:
0.87
Capitalizzazione di mercato:
$571.08M
Reddito:
$50.27M
Utile/perdita netta:
$-68.91M
Rapporto P/E:
-7.5456
EPS:
-0.603
Flusso di cassa netto:
$-44.32M
1 W Prestazione:
-2.78%
1M Prestazione:
-15.43%
6M Prestazione:
+10.17%
1 anno Prestazione:
-21.14%
Intervallo 1D:
$4.425
$4.595
Intervallo di 1 settimana:
$4.425
$4.775
Portata 52W:
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Nome
Aquestive Therapeutics Inc
Settore
Telefono
908-941-1900
Indirizzo
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.55 | 587.39M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Ripresa | Oppenheimer | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2019-04-22 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-03 | Iniziato | Lake Street | Buy |
| 2018-08-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-08-20 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST) - Seeking Alpha
Form 8K Aquestive Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Aquestive appoints Rich Daly to board of directors By Investing.com - Investing.com India
Aquestive appoints Rich Daly to board of directors - Investing.com
Aquestive Therapeutics elects Richard J. Daly to its Board as Class I director - TradingView
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly - Yahoo Finance
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
Aquestive Therapeutics posts investor presentation; NDA resubmission for Anaphylm, $98.5M cash - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire
Anaphylm returns to FDA after Aquestive addresses usability, PK concerns - AllSci
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Aquestive Therapeutics CEO Barber Daniel Offloads 25,000 Shares at $4.82 Each - Kalkine Media
Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment - Benzinga
Aquestive resubmits Anaphylm FDA application for anaphylaxis - grafa.com
Aquestive resubmits drug application for anaphylaxis treatment By Investing.com - Investing.com Australia
Aquestive resubmits drug application for anaphylaxis treatment - Investing.com
Aquestive Therapeutics Resubmits NDA for Anaphylm Sublingual Film After Positive Human Factors and PK Study Results - Quiver Quantitative
Allergy film that cuts dosing time resubmitted by Aquestive (NASDAQ: AQST) - Stock Titan
Aquestive Therapeutics Announces Resubmission of New Drug - globenewswire.com
Aquestive Therapeutics CEO Barber sells $120,487 in shares By Investing.com - Investing.com Nigeria
Aquestive Therapeutics CEO Barber sells $120,487 in shares - Investing.com
Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Barber Daniel - Moomoo
Aquestive Therapeutics (AQST) CEO sells 25,000 shares in preset plan trade - Stock Titan
Aquestive Therapeutics CCO Executes 8,750 Share Sale Following Option Exercise Under 10b5-1 Plan - Kalkine Media
Aquestive (NASDAQ: AQST) CCO sells 8,750 shares after exercising options - Stock Titan
Cantor Fitzgerald reiterates Aquestive stock Overweight on Anaphylm profile By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) insider adds 2,293 shares - Stock Titan
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) CEO boosts stake with warrant exercise - Stock Titan
Aquestive Therapeutics (AQST) COO adds shares via warrant exercise - Stock Titan
Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jung Cassie - Moomoo
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - accessnewswire.com
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress - TipRanks
Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive reports study results for Anaphylm allergy treatment By Investing.com - Investing.com Nigeria
Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) - Seeking Alpha
Aquestive (AQST) Q2 2026 Earnings Call Transcript - AOL.com
Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Aquestive (AQST) Closing Snapshot: Records a 0.70% Increase to $4.32 in the Current Update; Technical Focus - Vinanet
Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $107,168 - Bitget
Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan - Stock Titan
Aquestive Therapeutics Inc Azioni (AQST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):